MGTX
Price
$8.00
Change
+$0.67 (+9.14%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
588.88M
49 days until earnings call
SCPH
Price
$5.63
Change
-$0.01 (-0.18%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
301.67M
48 days until earnings call
Interact to see
Advertisement

MGTX vs SCPH

Header iconMGTX vs SCPH Comparison
Open Charts MGTX vs SCPHBanner chart's image
MeiraGTx Holdings
Price$8.00
Change+$0.67 (+9.14%)
Volume$13.74K
Capitalization588.88M
scPharmaceuticals
Price$5.63
Change-$0.01 (-0.18%)
Volume$2.18K
Capitalization301.67M
MGTX vs SCPH Comparison Chart in %
Loading...
MGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MGTX vs. SCPH commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGTX is a Hold and SCPH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (MGTX: $7.34 vs. SCPH: $5.63)
Brand notoriety: MGTX and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MGTX: 79% vs. SCPH: 98%
Market capitalization -- MGTX: $588.88M vs. SCPH: $301.67M
MGTX [@Biotechnology] is valued at $588.88M. SCPH’s [@Biotechnology] market capitalization is $301.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MGTX’s FA Score shows that 0 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • MGTX’s FA Score: 0 green, 5 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, SCPH is a better buy in the long-term than MGTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MGTX’s TA Score shows that 3 TA indicator(s) are bullish while SCPH’s TA Score has 4 bullish TA indicator(s).

  • MGTX’s TA Score: 3 bullish, 5 bearish.
  • SCPH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than MGTX.

Price Growth

MGTX (@Biotechnology) experienced а -2.07% price change this week, while SCPH (@Biotechnology) price change was +0.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.96%. For the same industry, the average monthly price growth was +12.81%, and the average quarterly price growth was +39.84%.

Reported Earning Dates

MGTX is expected to report earnings on Nov 06, 2025.

SCPH is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MGTX($589M) has a higher market cap than SCPH($302M). SCPH YTD gains are higher at: 59.040 vs. MGTX (20.443). SCPH has higher annual earnings (EBITDA): -85.55M vs. MGTX (-132.21M). SCPH has more cash in the bank: 40.8M vs. MGTX (32.2M). SCPH has less debt than MGTX: SCPH (52.4M) vs MGTX (80.5M). SCPH has higher revenues than MGTX: SCPH (50M) vs MGTX (37.9M).
MGTXSCPHMGTX / SCPH
Capitalization589M302M195%
EBITDA-132.21M-85.55M155%
Gain YTD20.44359.04035%
P/E RatioN/AN/A-
Revenue37.9M50M76%
Total Cash32.2M40.8M79%
Total Debt80.5M52.4M154%
FUNDAMENTALS RATINGS
MGTX vs SCPH: Fundamental Ratings
MGTX
SCPH
OUTLOOK RATING
1..100
5317
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5038
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for MGTX (96) in the Biotechnology industry. This means that SCPH’s stock grew somewhat faster than MGTX’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MGTX (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to MGTX’s over the last 12 months.

SCPH's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as MGTX (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to MGTX’s over the last 12 months.

SCPH's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as MGTX (50) in the Biotechnology industry. This means that SCPH’s stock grew similarly to MGTX’s over the last 12 months.

SCPH's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MGTX (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to MGTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MGTXSCPH
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
83%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 21 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEVCX22.44N/A
N/A
First Eagle US C
CSXAX54.93N/A
N/A
Calvert US Large Cap Core Rspnb Idx A
WSCRX36.71N/A
N/A
Allspring Small Company Growth R6
CSDGX15.76N/A
N/A
Copeland SMID Cap Dividend Growth A
MSDUX15.04N/A
N/A
Morgan Stanley Emerging Mkt ex China I

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with AUTL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then AUTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
+0.18%
AUTL - SCPH
42%
Loosely correlated
-4.17%
IPSC - SCPH
40%
Loosely correlated
+1.37%
OCUL - SCPH
39%
Loosely correlated
-2.17%
ATAI - SCPH
39%
Loosely correlated
-0.65%
AURA - SCPH
38%
Loosely correlated
-3.02%
More